Literature DB >> 15135892

Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.

Yan Qi Liang1, Xi Can Tang.   

Abstract

The cholinesterase inhibitors huperzine A, donepezil and rivastigmine were compared for their effects on extracellular acetylcholine concentration and acetylcholinesterase activity in the rat cortex. After i.p. injection, huperzine A (0.25-0.75 micromol/kg), donepezil (2-6 micromol/kg) and rivastigmine (0.75-1.5 micromol/kg) dose-dependently elevated the concentration of acetylcholine. The duration of huperzine A was longest. The time courses of cortical acetylcholinesterase inhibition with middle doses of these agents mirrored the increases of acetylcholine at the same doses. However, acetylcholinesterase inhibition was disproportionately greater after middle dose of rivastigmine than doses of huperzine A and donepezil that increased acetylcholine to a similar extent. Muscle fasciculation appeared only after donepezil with a dose-dependent incidence and intensity. In molar terms, huperzine A was 8- and 2-fold more potent than donepezil and rivastigmine, respectively, in increasing cortical acetylcholine levels, with a longer-lasting effect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135892     DOI: 10.1016/j.neulet.2003.12.071

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

Review 1.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

2.  Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats.

Authors:  Blake A Kimmey; Laura E Rupprecht; Matthew R Hayes; Heath D Schmidt
Journal:  Addict Biol       Date:  2012-12-12       Impact factor: 4.280

Review 3.  Huperzine A for mild cognitive impairment.

Authors:  Jirong Yue; Bi Rong Dong; Xiufang Lin; Ming Yang; Hong Mei Wu; Taixiang Wu
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Total synthesis of (+)-complanadine A using an iridium-catalyzed pyridine C-H functionalization.

Authors:  Daniel F Fischer; Richmond Sarpong
Journal:  J Am Chem Soc       Date:  2010-05-05       Impact factor: 15.419

5.  Multiple-targeting and conformational selection in the estrogen receptor: computation and experiment.

Authors:  Peng Yuan; Kaiwei Liang; Buyong Ma; Nan Zheng; Ruth Nussinov; Jian Huang
Journal:  Chem Biol Drug Des       Date:  2011-04-27       Impact factor: 2.817

6.  Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease.

Authors:  Jing-ying Jia; Qian-hua Zhao; Yun Liu; Yu-zhou Gui; Gang-yi Liu; Da-yuan Zhu; Chen Yu; Zhen Hong
Journal:  Acta Pharmacol Sin       Date:  2013-04-29       Impact factor: 6.150

7.  Huperzine A inhibits immediate addictive behavior but not behavioral sensitization following repeated morphine administration in rats.

Authors:  Jinling Sun; Lin Tian; Ruisi Cui; Xinwang Li
Journal:  Exp Ther Med       Date:  2017-02-02       Impact factor: 2.447

8.  Donepezil is ineffective in promoting motor and cognitive benefits after controlled cortical impact injury in male rats.

Authors:  Kaitlyn E Shaw; Corina O Bondi; Samuel H Light; Lire A Massimino; Rose L McAloon; Christina M Monaco; Anthony E Kline
Journal:  J Neurotrauma       Date:  2013-03-26       Impact factor: 5.269

Review 9.  Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase.

Authors:  Hai Yan Zhang; Han Yan; Xi Can Tang
Journal:  Cell Mol Neurobiol       Date:  2007-07-27       Impact factor: 5.046

Review 10.  Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.

Authors:  Ana Sofía Vallés; María Virginia Borroni; Francisco J Barrantes
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.